Koers Cronos Group Inc Toronto S.E.
Aandelen
CA22717L1013
Farmaceutische producten
Omzet 2024 * | 141 mln. 103 mln. 95,44 mln. | Omzet 2025 * | 169 mln. 123 mln. 115 mln. | Marktkapitalisatie | 1,45 mld. 1,06 mld. 986 mln. |
---|---|---|---|---|---|
Nettowinst (verlies) 2024 * | -17 mln. -12,42 mln. -11,54 mln. | Nettowinst (verlies) 2025 * | 7 mln. 5,12 mln. 4,75 mln. | EV/omzet 2024 * | 1,88 x |
Nettoliquiditeiten 2024 * | 1,19 mld. 867 mln. 806 mln. | Nettoliquiditeiten 2025 * | 1,19 mld. 870 mln. 809 mln. | EV/omzet 2025 * | 1,54 x |
K/w-verhouding 2024 * |
-99,3
x | K/w-verhouding 2025 * |
-328
x | Werknemers | - |
Dividendrendement 2024 * |
-
| Dividendrendement 2025 * |
-
| Vrij verhandelbaar | 52,38% |
Recentste transcriptie over Cronos Group Inc
Managers | Titel | Leeftijd | Van |
---|---|---|---|
Chief Executive Officer | 37 | 06-11-15 | |
James Holm
DFI | Director of Finance/CFO | 41 | 14-11-22 |
Arye Weigensberg
CTO | Chief Tech/Sci/R&D Officer | 41 | - |
Besturend | Titel | Leeftijd | Van |
---|---|---|---|
Director/Board Member | 48 | 25-06-21 | |
James D. Rudyk
BRD | Director/Board Member | 57 | 01-02-18 |
Jason Adler
BRD | Director/Board Member | 52 | 12-07-16 |
Vaira. 1 jan. | Kapi. | |
---|---|---|
+40,09% | 6,16 mld. | |
-16,34% | 4,46 mld. | |
-7,11% | 3,27 mld. | |
+5,14% | 3,2 mld. | |
-0,18% | 2,6 mld. | |
+47,93% | 1,98 mld. | |
-7,15% | 1,7 mld. | |
+0,67% | 1,66 mld. | |
-8,73% | 1,61 mld. |